Innoviva (INVA) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.45% |
| Sep 30, 2025 | 21.03% |
| Jun 30, 2025 | 5.10% |
| Mar 31, 2025 | -28.17% |
| Sep 30, 2024 | 16.71% |
| Jun 30, 2024 | -12.83% |
| Mar 31, 2024 | -49.80% |
| Sep 30, 2023 | -23.53% |
| Jun 30, 2023 | -13.57% |
| Mar 31, 2023 | -26.05% |
| Sep 30, 2022 | 55.90% |
| Jun 30, 2022 | 32.45% |
| Mar 31, 2022 | -18.23% |
| Sep 30, 2021 | -41.33% |
| Jun 30, 2021 | -43.90% |
| Mar 31, 2021 | 47.23% |
| Dec 31, 2020 | -37.38% |
| Sep 30, 2020 | 24.01% |
| Jun 30, 2020 | 48.77% |
| Mar 31, 2020 | 10.73% |
| Dec 31, 2019 | 45.93% |
| Sep 30, 2019 | 18.64% |
| Jun 30, 2019 | -1.49% |
| Mar 31, 2019 | 16.54% |
| Dec 31, 2018 | 19.98% |
| Sep 30, 2018 | -7.14% |
| Jun 30, 2018 | 23.72% |
| Mar 31, 2018 | -17.81% |
| Dec 31, 2017 | -30.21% |
| Sep 30, 2017 | 17.30% |
| Jun 30, 2017 | -17.28% |
| Mar 31, 2017 | 27.52% |
| Dec 31, 2016 | 27.60% |
| Sep 30, 2016 | 6.69% |
| Jun 30, 2016 | 7.46% |
| Mar 31, 2016 | 13.70% |
| Dec 31, 2015 | -4.31% |
| Sep 30, 2015 | -60.65% |